Last week, something truly amazing happened…
Noland Arbaugh, a 29-year-old quadriplegic man, played chess on his laptop by moving the cursor using his brain.
No, he wasn’t born telekinetic. Instead, he’s the first recipient of Elon Musk’s Neuralink implant, which is a brain-computer interface designed to help people overcome neurological disorders. Perhaps serving as a cure for neurodegenerative diseases and paralysis.
I know Musk can be a controversial figure, but no matter what you think about the man, neuralink is going to prove to be one of the greatest inventions of the 21st century.
Make no mistake: the promise of neuralink is not trivial. Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
If Musk’s predictions come to fruition (much in the way they already did with electric cars and reusable rockets), neuralink will allow blind people to see, deaf people to hear, and the paralyzed to walk, talk, and breathe without the assistance of any other medical devices.
This really is groundbreaking stuff.
The only thing actually comparable to neuralink is EN-23, the valuable class of molecules that has the potential to essentially “rewire” the brain in a way that could not only help treat neurological disorders, but actually increase comprehension and heighten intelligence
Worth noting, Musk already uses EN-23 himself and Steve Jobs also took it, calling it one of the most important things in his life.
Bill Gates and billionaire GoDaddy Founder Bob Parsons have also taken EN-23, as well as Google co-founder Sergey Brin.
It’s really no coincidence that some of the wealthiest and most successful people in the world take EN-23. After all, EN-23 has been proven to enhance cognitive performance. But until recently it’s only been available to the wealthy elite.
That could all change on August 11th.
You see, for the past 50 years, EN-23 has been illegal to produce, distribute or consume. It was actually considered to be a dangerous drug until the FDA started fast-tracking research on it.
Now, there are more than a dozen FDA clinical trials underway that are testing EN-23 medications for the treatment of everything from depression and anxiety to PTSD and addiction. And one of those trials proved successful last year. Which means the FDA is now slated to approve it on August 11th.
The company expected to bring this new EN-23 medication to market is called Lykos Therapeutics, and it’ll be available for veterans suffering from PTSD.
Now Lykos Therapeutics is not a public company, but there are three other EN-23 companies that are. Two of the companies have been fast-tracked by the FDA, and we expect the third to receive fast-track approval later this year.
The two stocks that have already been fast-tracked soared on the news.
Check it out …
Based on our checks, we believe the third will be fast-tracked in just a few weeks. Which is why I’m telling you about this today.
I want to make sure you have the opportunity to buy a few shares before that happens. So I put together this short presentation on EN-23, which includes a detailed analysis about this stock, as well as a couple other EN-23 stocks that we believe will make us a ton of cash over the next few weeks.
You can download it for free here. To a new way of life and a new generation of wealth… Jeff Siegel
@JeffSiegel on Twitter
Check us out on YouTube!Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
